Device Trial Radar · NCT04879940
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Feb 23, 2022
Primary completion
Jun 16, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II prospective clinical trial in which patients with prostate carcinoma and obstructive lower urinary tract symptoms electing for radiation therapy will undergo Prostatic Artery Embolization (PAE) prior to treatment. PAE will be administered by Interventional Radiology. Patients will be seen for follow-up at 6 weeks and 12 weeks following PAE after which they will start definitive radiotherapy. After completion of radiotherapy the patient will be seen at 12 weeks
Conditions
- Prostate Carcinoma
- Benign Prostatic Hyperplasia
Interventions
Merit Medical EmbospheresDevice
Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
Radiation TherapyRadiation
Patients will undergo standard of care definitive radiation therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in International Prostate Symptom ScoreTime frame: At screening, Day of PAE, and 6 weeks & 12 weeks after PAE
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.